OIL Stock Overview
Engages in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications in Australia, Germany, China, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Optiscan Imaging Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.19 |
| 52 Week High | AU$0.26 |
| 52 Week Low | AU$0.072 |
| Beta | 1.2 |
| 11 Month Change | 2.70% |
| 3 Month Change | -24.00% |
| 1 Year Change | 160.27% |
| 33 Year Change | -13.64% |
| 5 Year Change | 341.86% |
| Change since IPO | 280.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| OIL | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 26.7% | 0.3% | 0.3% |
| 1Y | 160.3% | 12.3% | 16.0% |
Return vs Industry: OIL exceeded the Australian Medical Equipment industry which returned 12.3% over the past year.
Return vs Market: OIL exceeded the Australian Market which returned 16% over the past year.
Price Volatility
| OIL volatility | |
|---|---|
| OIL Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 9.5% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: OIL's share price has been volatile over the past 3 months.
Volatility Over Time: OIL's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Camile Farah | www.optiscan.com |
Optiscan Imaging Limited engages in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications in Australia, Germany, China, and the United States. It offers InVivage, an intra-oral endomicroscope for oral cancer imaging; InVue, a microscopic medical imaging device for precision surgery; and ViewnVivo, an endomicroscope for life sciences, pre-clinical and translational research. The company has a collaboration agreement with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system for applications in robotic surgery.
Optiscan Imaging Limited Fundamentals Summary
| OIL fundamental statistics | |
|---|---|
| Market cap | AU$158.71m |
| Earnings (TTM) | -AU$6.06m |
| Revenue (TTM) | AU$2.99m |
53.2x
P/S Ratio-26.2x
P/E RatioIs OIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OIL income statement (TTM) | |
|---|---|
| Revenue | AU$2.99m |
| Cost of Revenue | AU$526.20k |
| Gross Profit | AU$2.46m |
| Other Expenses | AU$8.52m |
| Earnings | -AU$6.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0073 |
| Gross Margin | 82.38% |
| Net Profit Margin | -202.96% |
| Debt/Equity Ratio | 0.3% |
How did OIL perform over the long term?
See historical performance and comparison